Search - tctmd.com

Displaying 421 - 440 of 568

Sort: Relevancy | Date

Presentation ACC 2015

Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

Presenter: Marc S. Sabatine

March 14, 2015

Presentation

ITALIC: 6- vs 24-Month DAPT After Implantation of DES in Patients Nonresistant to Aspirin

Presenter: Martine Gilard

March 10, 2015

Presentation CADECI 2015

Uso responsable de Rivaroxabán en prevención secundaria después de un SCA:Casos clínicos_

Presenter: DR. JOSE LUIS LEIVA PONS

February 20, 2015

Presentation

LAA Occlusion for Stroke Prevention in A-Fib

Presenter: Apostolos Tzikas

January 29, 2015

Presentation

Utilization and Adverse Outcomes of Percutaneous LAA Closure for Stroke Prevention in A-fib in the US

Presenter: AO Badheka

December 11, 2014

Presentation

Incidence, Source, Determinants, and Prognostic Impact of Major Bleeding in Stable CAD

Presenter: M. Hanon

September 30, 2014

Presentation TCT 2014

Neurological Complications of TEVAR: Prevention and Management

Presenter: Wilson Y. Szeto, Rodney White, Frank J. Criado, Alan B. Lumsden

September 16, 2014

Presentation TCT 2014

Flash Debate: Statins for Contrast Nephropathy Prevention Ready for Prime Time? Con!

Presenter: Antonio L. Bartorelli, Somjot S. Brar, Roxana Mehran, Richard Solomon

September 16, 2014

Presentation TCT 2014

Cost-effectiveness Analysis Of Left Atrial Appendage Occlusion Device Compared With 7 Oral Anticoagulants For Stroke Prevention In Atrial Fibrillation

Presenter: Vivian Lee

September 16, 2014

Presentation TCT 2014

TCT 170: Cost-effectiveness Analysis of a Left Atrial Appendage Occlusion Device Compared with 7 Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation

Presenter: Saibal Kar, Bushra S Rana, Jai-Wun Park, Vivian Lee

September 15, 2014

Presentation TCT 2014

When Should Aspirin Be Dropped From Triple Therapy? Musings on Woest and Beyond

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Harvey D. White

September 15, 2014

Presentation TCT 2014

Old and New Anticoagulants for Stroke Prevention: Benefits and Risks

Presenter: Josep Rodés-Cabau, Brian K. Whisenant, David Hildick-Smith, Jonathan L. Halperin

September 15, 2014

Presentation TCT 2014

No: Vorapaxar Is Effective, but Prasugrel and Ticagrelor are Preferred!

Presenter: Dirk Sibbing

September 14, 2014

Presentation TCT 2014

Yes: TRA-2P Has Proven it!

Presenter: David J. Moliterno

September 14, 2014

Presentation TCT 2014

Integrating a WOEST Aspirin Deletion Strategy Into Clinical Practice: When Is it Appropriate?

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Freek W.A. Verheugt

September 14, 2014

Presentation TCT 2014

NO: Cangrelor Is No Champion Next to the Appropriate Use of Potent Oral Antiplatelet Agents!

Presenter: Dimitrios Alexopoulos

September 14, 2014

Presentation TCT 2014

YES: CHAMPION PHOENIX was Convincing!

Presenter: Deepak L. Bhatt

September 14, 2014

Presentation TCT 2014

Yes: WOEST Definititely Proves Safety and Likely Efficacy as Well!

Presenter: Harvey D. White

September 14, 2014

Presentation TCT 2014

Featured Lecture: Aspirin, the Most Understood and Misunderstood Antiplatelet Agent

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Anthony A. Bavry

September 14, 2014

Presentation TCT 2014

Can LAA Closure Become the New Standard for Stroke Prevention?

Presenter: Hilary Nierenberg, Julie Logan, Saibal Kar

September 14, 2014

Advertisement

Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

ITALIC: 6- vs 24-Month DAPT After Implantation of DES in Patients Nonresistant to Aspirin

Uso responsable de Rivaroxabán en prevención secundaria después de un SCA:Casos clínicos_

LAA Occlusion for Stroke Prevention in A-Fib

Utilization and Adverse Outcomes of Percutaneous LAA Closure for Stroke Prevention in A-fib in the US

Incidence, Source, Determinants, and Prognostic Impact of Major Bleeding in Stable CAD

Neurological Complications of TEVAR: Prevention and Management

Flash Debate: Statins for Contrast Nephropathy Prevention Ready for Prime Time? Con!

Cost-effectiveness Analysis Of Left Atrial Appendage Occlusion Device Compared With 7 Oral Anticoagulants For Stroke Prevention In Atrial Fibrillation

TCT 170: Cost-effectiveness Analysis of a Left Atrial Appendage Occlusion Device Compared with 7 Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation

When Should Aspirin Be Dropped From Triple Therapy? Musings on Woest and Beyond

Old and New Anticoagulants for Stroke Prevention: Benefits and Risks

No: Vorapaxar Is Effective, but Prasugrel and Ticagrelor are Preferred!

Yes: TRA-2P Has Proven it!

Integrating a WOEST Aspirin Deletion Strategy Into Clinical Practice: When Is it Appropriate?

NO: Cangrelor Is No Champion Next to the Appropriate Use of Potent Oral Antiplatelet Agents!

YES: CHAMPION PHOENIX was Convincing!

Yes: WOEST Definititely Proves Safety and Likely Efficacy as Well!

Featured Lecture: Aspirin, the Most Understood and Misunderstood Antiplatelet Agent

Can LAA Closure Become the New Standard for Stroke Prevention?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content